FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169421618> ?p ?o ?g. }

• W2169421618 endingPage "235" @default.
• W2169421618 startingPage "229" @default.
• W2169421618 abstract "<h2>Summary</h2><h3>Background</h3> In a previous randomised controlled phase 2 trial, intravenous infusion of salbutamol for up to 7 days in patients with acute respiratory distress syndrome (ARDS) reduced extravascular lung water and plateau airway pressure. We assessed the effects of this intervention on mortality in patients with ARDS. <h3>Methods</h3> We did a multicentre, placebo-controlled, parallel-group, randomised trial at 46 UK intensive-care units between December, 2006, and March, 2010. Intubated and mechanically ventilated patients (aged ≥16 years) within 72 h of ARDS onset were randomly assigned to receive either salbutamol (15 μg/kg ideal bodyweight per h) or placebo for up to 7 days. Randomisation was done by a central telephone or web-based randomisation service with minmisation by centre, pressure of arterial oxygen to fractional inspired oxygen concentration (PaO₂/F_IO₂) ratio, and age. All participants, caregivers, and investigators were masked to group allocation. The primary outcome was death within 28 days of randomisation. Analysis was by intention-to-treat. This trial is registered, ISRCTN38366450 and EudraCT number 2006-002647-86. <h3>Findings</h3> We randomly assigned 162 patients to the salbutamol group and 164 to the placebo group. One patient in each group withdrew consent. Recruitment was stopped after the second interim analysis because of safety concerns. Salbutamol increased 28-day mortality (55 [34%] of 161 patients died in the salbutamol group <i>vs</i> 38 (23%) of 163 in the placebo group; risk ratio [RR] 1·47, 95% CI 1·03–2·08). <h3>Interpretation</h3> Treatment with intravenous salbutamol early in the course of ARDS was poorly tolerated. Treatment is unlikely to be beneficial, and could worsen outcomes. Routine use of β-2 agonist treatment in ventilated patients with this disorder cannot be recommended. <h3>Funding</h3> UK Medical Research Council, UK Department of Health, UK Intensive Care Foundation." @default.
• W2169421618 created "2016-06-24" @default.
• W2169421618 creator A5019138306 @default.
• W2169421618 creator A5023908206 @default.
• W2169421618 creator A5039309548 @default.
• W2169421618 creator A5041103166 @default.
• W2169421618 creator A5050958004 @default.
• W2169421618 creator A5059014594 @default.
• W2169421618 creator A5068995535 @default.
• W2169421618 creator A5070952344 @default.
• W2169421618 date "2012-01-01" @default.
• W2169421618 modified "2023-10-15" @default.
• W2169421618 title "Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial" @default.
• W2169421618 cites W1903803846 @default.
• W2169421618 cites W1978960863 @default.
• W2169421618 cites W1994505525 @default.
• W2169421618 cites W2013256551 @default.
• W2169421618 cites W2013725292 @default.
• W2169421618 cites W2033812304 @default.
• W2169421618 cites W2051370790 @default.
• W2169421618 cites W2053627700 @default.
• W2169421618 cites W2064017658 @default.
• W2169421618 cites W2068854215 @default.
• W2169421618 cites W2097321968 @default.
• W2169421618 cites W2100907993 @default.
• W2169421618 cites W2103070525 @default.
• W2169421618 cites W2103107317 @default.
• W2169421618 cites W2110707896 @default.
• W2169421618 cites W2115186092 @default.
• W2169421618 cites W2130055391 @default.
• W2169421618 cites W2137300449 @default.
• W2169421618 cites W2155341761 @default.
• W2169421618 cites W2156485933 @default.
• W2169421618 cites W2161328469 @default.
• W2169421618 cites W2163329325 @default.
• W2169421618 cites W2314787815 @default.
• W2169421618 cites W2330652094 @default.
• W2169421618 cites W2333411966 @default.
• W2169421618 cites W2597070792 @default.
• W2169421618 cites W3042153938 @default.
• W2169421618 doi "https://doi.org/10.1016/s0140-6736(11)61623-1" @default.
• W2169421618 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3266479" @default.
• W2169421618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22166903" @default.
• W2169421618 hasPublicationYear "2012" @default.
• W2169421618 type Work @default.
• W2169421618 sameAs 2169421618 @default.
• W2169421618 citedByCount "294" @default.
• W2169421618 countsByYear W21694216182012 @default.
• W2169421618 countsByYear W21694216182013 @default.
• W2169421618 countsByYear W21694216182014 @default.
• W2169421618 countsByYear W21694216182015 @default.
• W2169421618 countsByYear W21694216182016 @default.
• W2169421618 countsByYear W21694216182017 @default.
• W2169421618 countsByYear W21694216182018 @default.
• W2169421618 countsByYear W21694216182019 @default.
• W2169421618 countsByYear W21694216182020 @default.
• W2169421618 countsByYear W21694216182021 @default.
• W2169421618 countsByYear W21694216182022 @default.
• W2169421618 countsByYear W21694216182023 @default.
• W2169421618 crossrefType "journal-article" @default.
• W2169421618 hasAuthorship W2169421618A5019138306 @default.
• W2169421618 hasAuthorship W2169421618A5023908206 @default.
• W2169421618 hasAuthorship W2169421618A5039309548 @default.
• W2169421618 hasAuthorship W2169421618A5041103166 @default.
• W2169421618 hasAuthorship W2169421618A5050958004 @default.
• W2169421618 hasAuthorship W2169421618A5059014594 @default.
• W2169421618 hasAuthorship W2169421618A5068995535 @default.
• W2169421618 hasAuthorship W2169421618A5070952344 @default.
• W2169421618 hasBestOaLocation W21694216181 @default.
• W2169421618 hasConcept C126322002 @default.
• W2169421618 hasConcept C141983124 @default.
• W2169421618 hasConcept C142724271 @default.
• W2169421618 hasConcept C168563851 @default.
• W2169421618 hasConcept C204787440 @default.
• W2169421618 hasConcept C27081682 @default.
• W2169421618 hasConcept C2776042228 @default.
• W2169421618 hasConcept C2776348555 @default.
• W2169421618 hasConcept C2777080012 @default.
• W2169421618 hasConcept C2777394947 @default.
• W2169421618 hasConcept C2777714996 @default.
• W2169421618 hasConcept C2780807750 @default.
• W2169421618 hasConcept C42219234 @default.
• W2169421618 hasConcept C61943457 @default.
• W2169421618 hasConcept C71924100 @default.
• W2169421618 hasConceptScore W2169421618C126322002 @default.
• W2169421618 hasConceptScore W2169421618C141983124 @default.
• W2169421618 hasConceptScore W2169421618C142724271 @default.
• W2169421618 hasConceptScore W2169421618C168563851 @default.
• W2169421618 hasConceptScore W2169421618C204787440 @default.
• W2169421618 hasConceptScore W2169421618C27081682 @default.
• W2169421618 hasConceptScore W2169421618C2776042228 @default.
• W2169421618 hasConceptScore W2169421618C2776348555 @default.
• W2169421618 hasConceptScore W2169421618C2777080012 @default.
• W2169421618 hasConceptScore W2169421618C2777394947 @default.
• W2169421618 hasConceptScore W2169421618C2777714996 @default.
• W2169421618 hasConceptScore W2169421618C2780807750 @default.
• W2169421618 hasConceptScore W2169421618C42219234 @default.
• W2169421618 hasConceptScore W2169421618C61943457 @default.

• next